Significant agreements - Novartis Collaboration Agreement (Details) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Nov. 30, 2025 |
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Mar. 27, 2023
item
|
|
| Significant agreements. | ||||||||
| Revenue from collaborative arrangement | $ 34,057,000 | $ 11,734,000 | $ 35,573,000 | $ 24,631,000 | ||||
| Deferred revenue | 3,692,000 | 3,692,000 | $ 38,469,000 | $ 101,658,000 | ||||
| Novartis | ||||||||
| Significant agreements. | ||||||||
| Number of collaboration targets | item | 2 | |||||||
| Revenue from collaborative arrangement | 0 | $ 2,181,000 | 0 | $ 5,077,000 | ||||
| Deferred revenue | $ 0 | $ 0 | $ 0 | $ 44,073,000 | ||||
| Threshold period of notice required for termination of agreement | 90 days | |||||||
| X | ||||||||||
- Definition Number of collaboration targets under the collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition Represents the threshold period of notice required for termination of agreement. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|